• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

    1/17/23 8:00:00 AM ET
    $AGRX
    $GNTA
    $NMTR
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGRX alert in real time by email

    Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management.

    During his tenure at BDSI, Mark was responsible for creating and overseeing the implementation of the company's corporate strategy and overseeing all business operations. Additionally, Mark executed on the development, NDA approval, and commercialization of three products in neurological and pain indications, Onsolis®, Bunavail®, and Belbuca®. BDSI was successfully sold to Collegium Pharmaceutical, Inc. in March 2022.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch indicated for the treatment of mild, moderate, and severe dementia in Alzheimer's patients.

    Mark joins Corium Pharma Solutions shortly after its formation in October 2022, when Webster Equity Partners ("Webster") acquired the standalone business unit from its former, commercial-stage biopharmaceutical parent company, Corium. Corium's original investor, Gurnet Point Capital ("Gurnet Point"), remains as a joint owner in Corium Pharma Solutions and each Gurnet Point and Webster have equal board representation.

    "I am thrilled to welcome Mark as Chief Executive Officer of Corium Pharma Solutions," said Travis Wilson, Partner at Gurnet Point. "Mark's decades of industry experience and proven track record of research, development, and commercialization of pharmaceutical products make him the ideal leader for the next phase of Corium Pharma Solutions' growth. He is uniquely qualified to step into the leadership role and Corium Pharma Solutions will benefit from his deep product development, regulatory, and commercial experience across numerous therapeutics areas."

    "I am excited to have the opportunity to lead the Corium Pharma Solutions team as we continue to build on the company's historical successes and further establish its leadership position in transdermal contract development and manufacturing," said Dr. Mark Sirgo, Chief Executive Officer. "With the backing and financial support of Gurnet Point and Webster, I look forward to focusing on both supporting our current partners and procuring new business opportunities within our current capabilities, while selectively adding to our breadth of specialty offerings through M&A to extend our commercial product footprint."

    Prior to founding BDSI, Mark was Senior Vice President, Global Business Development at PPD, Inc., where he managed global sales and marketing for one of the world's largest contract research organizations serving biopharmaceutical, pharmaceutical, and device industries. Further, he held several leadership positions at GSK plc in clinical development and marketing and was a Director at Salix Pharmaceuticals, Ltd. prior to its sale to Valeant Pharmaceuticals International, Inc. in 2015. Mark also currently serves as Chairman of 9 Meters Biopharma, Inc. (NASDAQ:NMTR) and Genenta Science SpA (NASDAQ:GNTA).

    Dr. Sirgo holds a PharmD from Philadelphia College of Pharmacy and Sciences, and a BS in Pharmacy from The Ohio State University.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Pharma Solutions offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by Gurnet Point Capital and Webster Equity Partners.

    About Gurnet Point Capital

    Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005355/en/

    Get the next $AGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGRX
    $GNTA
    $NMTR
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    5/1/2025$161.00Buy → Neutral
    Redburn Atlantic
    Procter & Gamble Company
    $PG
    4/25/2025$177.00Sector Perform → Outperform
    RBC Capital Mkts
    Procter & Gamble Company
    $PG
    11/25/2024$160.00 → $209.00Neutral → Buy
    DA Davidson
    Procter & Gamble Company
    $PG
    10/10/2024$159.00Neutral
    DA Davidson
    Procter & Gamble Company
    $PG
    9/30/2024$163.00Overweight → Equal Weight
    Barclays
    Procter & Gamble Company
    $PG
    9/24/2024$174.00Neutral
    Piper Sandler
    Procter & Gamble Company
    $PG
    8/29/2024$190.00Hold → Buy
    DZ Bank
    Procter & Gamble Company
    $PG
    7/24/2024$182.00 → $175.00Buy → Hold
    Jefferies
    More analyst ratings

    $AGRX
    $GNTA
    $NMTR
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Procter & Gamble downgraded by Redburn Atlantic with a new price target

      Redburn Atlantic downgraded Procter & Gamble from Buy to Neutral and set a new price target of $161.00

      5/1/25 7:44:23 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Procter & Gamble from Sector Perform to Outperform and set a new price target of $177.00

      4/25/25 8:25:38 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble upgraded by DA Davidson with a new price target

      DA Davidson upgraded Procter & Gamble from Neutral to Buy and set a new price target of $209.00 from $160.00 previously

      11/25/24 7:49:48 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • The New Swiffer Sweep + Mop Deluxe Elevates Your Everyday Clean with a Stick That Collapses in Half for Easy Storage in Small Spaces

      Finally, a clean that clicks. The Swiffer Sweeper's biggest innovation in 25+ years is an essential two-in-one cleaning tool that offers improved durability and storage According to a recent survey, the average person stores eighteen different cleaning products around the home1. As cluttered cleaning closets become increasingly more common, many are searching for a more compact yet effective solution. Enter the Swiffer Sweep + Mop Deluxe—the biggest innovation to the original Sweeper in 25+ years – offering users a sturdier stick that collapses in half to store almost anywhere, and 2-in-1 dry and wet cleaning capabilities allowing users to elevate their everyday clean while eliminating the

      5/1/25 9:39:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Laundry Just Got Juicer: Gain's® New Dual Bead In-Wash Scent Boosters Deliver Powerful Combos of Floral Freshness and Luscious Fruits

      New Piña + Plumeria and Strawberry + Shea Scent Combinations Offer Bold and Bright Experiences That May Cause Excessive Sniffing of Clothes Gain®, a brand known for delivering long-lasting and irresistible scents to your laundry, is excited to announce Gain® Tango Scent Boosters, an all-new lineup of fruity and floral bead combinations that create unexpected scent experiences. Gain® Tango Scent Boosters, which come in Strawberry + Shea and Piña + Plumeria scent varieties, add delight by providing bursts of fragrance up to 12 weeks from wash to wear. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501137856/en/ "We discovered a

      5/1/25 9:15:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    SEC Filings

    See more
    • SEC Form 8-K filed by Procter & Gamble Company

      8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      5/1/25 4:35:08 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 424B5 filed by Procter & Gamble Company

      424B5 - PROCTER & GAMBLE Co (0000080424) (Filer)

      4/29/25 5:14:13 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form FWP filed by Procter & Gamble Company

      FWP - PROCTER & GAMBLE Co (0000080424) (Subject)

      4/28/25 5:17:18 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/22/24 4:50:46 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/9/24 2:20:54 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/2/24 3:44:23 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GNTA
    $NMTR
    $PG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier exercised 10,520 shares at a strike of $80.29 and sold $1,669,200 worth of shares (10,520 units at $158.67) (SEC Form 4)

      4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

      5/6/25 9:43:06 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • CEO - Health Care Davis Jennifer L. sold $161,384 worth of shares (1,000 units at $161.38), decreasing direct ownership by 2% to 51,965 units (SEC Form 4)

      4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

      4/30/25 1:45:15 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Portman Robert Jones was granted 44 shares, increasing direct ownership by 1% to 3,280 units (SEC Form 4)

      4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

      3/12/25 1:40:16 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Financials

    Live finance-specific insights

    See more
    • P&G Announces Fiscal Year 2025 Third Quarter Results

      Net Sales -2%; Organic Sales +1% Diluted EPS and Core EPS $1.54, each +1% UPDATES FISCAL YEAR SALES and EPS GUIDANCE MAINTAINS CASH RETURN GUIDANCE The Procter & Gamble Company (NYSE:PG) reported third quarter fiscal year 2025 net sales of $19.8 billion, a decrease of two percent versus the prior year. Organic sales, which excludes the impacts of foreign exchange and acquisitions and divestitures, increased one percent versus the prior year. Diluted and core net earnings per share were $1.54, each an increase of 1% versus prior year. Operating cash flow was $3.7 billion, and net earnings were $3.8 billion for the quarter. Adjusted free cash flow productivity was 75%. Adjusted free cash

      4/24/25 7:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G Declares Dividend Increase

      The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared an increased quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after May 15, 2025 to Common Stock shareowners of record at the close of business on April 21, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on April 21, 2025. This represents a five percent increase compared to the prior quarterly dividend. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 c

      4/8/25 4:15:00 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G Announces Fiscal Year 2025 Second Quarter Results

      Net Sales +2%; Organic Sales +3% Diluted EPS $1.88, +34%; Core EPS $1.88, +2% MAINTAINS FISCAL YEAR SALES, EPS GROWTH AND CASH RETURN GUIDANCE The Procter & Gamble Company (NYSE:PG) reported second quarter fiscal year 2025 net sales of $21.9 billion, an increase of two percent versus the prior year. Organic sales, which excludes the impacts of foreign exchange and acquisitions and divestitures, increased three percent versus the prior year. Diluted net earnings per share were $1.88, an increase of 34% versus prior year, due primarily to a non-cash impairment of the carrying value of the Gillette intangible asset in the base year. Core earnings per share were $1.88, an increase of two

      1/22/25 7:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Leadership Updates

    Live Leadership Updates

    See more
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tide Teams Up with Marvel Studios to Highlight Stain Stories and Host Exclusive, First-Ever "Collateral Stains Screening" Experience for Marvel Studios' Captain America: Brave New World

      Tide Launches Most Powerful Clean and Best Stain Removal POD – in any Universe: Ultra Oxi Boost Power PODS Throughout the Marvel Cinematic Universe (MCU), collateral stains are a way of life. And, in the highly anticipated Marvel Studios' "Captain America: Brave New World," in theaters February 14, everyday people in the MCU sometimes have to face clouds of dirt, spilled coffee and guacamole stains that occur by virtue of being courtside to action-packed superhero moments. That's why Tide®, America's #1 trusted laundry detergent*, has joined forces with the film to show how the biggest stains in the universe demand the most powerful clean – in any universe. This press release features mu

      1/8/25 10:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Braun IPLs Light Up Group Chats with a Major Deal This Holiday Season

      This December, Braun is meeting shoppers where the best intel is shared, the group chat, and offering exclusive savings for gifts for family and friends. Group chats; love them, or hate them, everyone finds themselves in at least one quirky named chat that aptly represents its members. Group chats serve as a source of deep conversation, vacation plans that may or may not happen, inside jokes, and of course, the latest and greatest product recommendations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203470424/en/This holiday season, Braun is meeting shoppers where the best intel is shared, the group chat, and offering exc

      12/3/24 9:01:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary